5 Cheap Small-Cap Stocks to Buy Before the Next Breakout

Page 5 of 5

1. Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Number of Hedge Fund Investors In Q2 2023: 30

Latest Share Price: $7.55

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) develops drugs and offers research services to other companies. While analysts have continued to cut its revenue estimates following the latest earnings, the average share price target is $29.13 indicating significant long term potential.

30 out of the 910 hedge funds part of Insider Monkey’s Q2 2023 database own a stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS). Peter Kolchinsky’s RA Capital Management is the company’s largest stakeholder since it owns 4.3 million shares that are worth $45.6 million.

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)

Disclosure: None.  You can also take a look at Billionaire Chris Rokos is Selling These 12 Stocks in 2023 and 12 Stocks That Will Always Grow.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Follow Insider Monkey on Twitter

Page 5 of 5